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Widespread health service goals to improve consistency and safety in patient care have prompted considerable investment in the
development of evidence-based clinical guidelines. Computerised decision support (CDS) systems have been proposed as a means
to implement guidelines in practice. This paper discusses the general concept in oncology and presents an evaluation of a CDS system
to support triple assessment (TA) in breast cancer care. Balanced-block crossover experiment and questionnaire study. One stop
clinic for symptomatic breast patients. Twenty-four practising breast clinicians from United Kingdom National Health Service hospitals.
A web-based CDS system. Clinicians made significantly more deviations from guideline recommendations without decision support
(60 out of 120 errors without CDS; 16 out of 120 errors with CDS, Po0.001). Ignoring minor deviations, 16 potentially critical errors
arose in the no-decision-support arm of the trial compared with just one (P¼0.001) when decision support was available. Opinions
of participating clinicians towards the CDS tool became more positive after they had used it (Po0.025). The use of decision support
capabilities in TA may yield significant measurable benefits for quality and safety of patient care. This is an important option for
improving compliance with evidence-based practice guidelines.
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One of the most consistent findings in health services research is
the gap between evidence and practice (Grol and Grimshaw, 2003).
Consistent, safe, evidence-based health care has become a major
goal of many health-care systems, in developed countries in
particular, but is not always achieved (Kohn et al, 1999; Corrigan
et al, 2001). In the UK, it has been found that about 850000
medical errors occur in National Health Service hospitals every
year, resulting in some 40000 deaths (Aylin et al, 2004) and other
consequences. In 2001, the UK Audit Commission’s report on NHS
cancer care in England and Wales showed significant variation at
all stages of cancer care, including the criteria used by general
practitioners to refer patients, the diagnostic tests ordered and the
type of surgery, chemotherapy, and radiotherapy offered.
Such findings have fuelled worldwide interest in developing
clinical practice guidelines (CPGs) on the basis that they can be
expected to help improve quality of care by disseminating research
results and evidence-based practice more effectively. Many studies
have shown that CPGs can improve the quality of care (Cabana
et al, 1999; James and Hammond, 2000; Grimshaw et al, 2002). A
CPG is a ‘systematically developed statement to assist practitioner
and patient decisions about appropriate health care for specific
clinical circumstances’ (Field and Lohr, 1990 Institute of
Medicine).
In a special issue of BJC on Clinical Practice Guidelines for
cancer care (2001) Fervers, Hardy, and Philip introduce the SOR
(Standards, Options, and Recommendations) guidelines project of
the French Federation of Cancer Centers. Standards, Options, and
Recommendation is a major ongoing national project (http://
www.fnclcc.fr/) whose goal is to develop a methodology for the
progressive creation and maintenance of ‘CPGs for the initial
management of cancer in adults and children, for supportive care
and control of symptoms in cancer patients and for the
standardisation of ‘good clinical practice’ throughout the various
disciplines involved in cancer care. It has also undertaken the
developments of CPGs specifically for nursing and paramedical
staff, as well as the provision of evidence-based information for
patients. (Fervers et al, 2001).
The end result of the SOR development process is a document
(paper or electronic). A SOR document typically contains a
collection of ‘clinical algorithms’ to be consulted in appropriate
situations together with a succinct summary, rationale, and evidence
for the Standards, Options and criteria for Recommendations
covered by the algorithms. The BJC special issue includes articles
that describe a diverse set of 14 representative SOR guidelines,
covering common and less common cancers, developed by many
specialist groups. It documents 45 complete CPGs, involving
contributions from some 1700 doctors, pharmacists, and biologists.
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sBy any standards this is an impressive body of work, which
on the face of it could well justify the effort and resources that
Fervers et al (2001) emphasise is needed. The SOR programme has
attracted considerable international attention and extensive
collaborations with specialist cancer groups in the Canada, the
USA, and UK. Assuming that the methodology is rigorously
followed we may reasonably assume that the content of a SOR CPG
can be trusted, and assuming that the CPG is maintained properly
as new research is published such guidelines can be an important
continuing resource, facilitating discussion and new research as
well as specific clinical guidance.
There are, however, significant issues about the practical use of
practice guidelines, both SOR guidelines and other approaches.
Fervers et al (2001) themselves identify a number of obstacles,
including the problems of dissemination and continuing main-
tenance of the guideline content, which they refer to as the
‘aftercare’ problem. The question raised in this paper goes further,
asking about the use of and compliance with such guidelines in the
clinic. Although there is evidence of clinical value there are also
grounds for concern that the great potential value of the enormous
effort that goes into creating the guidelines may not be matched by
the level of adherence to them in practice (Bloom et al, 2004).
Furthermore a systematic review has found that traditional paper-
based dissemination of guidelines are relatively ineffective in
changing the behaviour of health-care professionals (Freemantle
et al, 1996).
Because of such concerns about the penetration of evidence-
based guidelines into routine clinical practice informaticians have
investigated techniques for bringing CPGs to the point of care in a
more useful form than documentary reminders and algorithms.
One prominent development is computerised Clinical Decision
Support Systems (CDSSs) which add value to conventional
guidelines by delivering options and recommendations in the
form of patient-specific suggestions. A recent systematic review of
CDSSs suggested that systems for disease management improve
practitioner compliance with guidelines: in the majority of
randomised trials (23 out of 37 studies, i.e. 62%) and demonstrated
a positive impact (Garg et al, 2005). Our group has developed a
series of CDSSs for use in cancer care with very promising results,
including a system for genetic risk assessment based on family
history (Emery et al, 2000), detection of abnormalities in
mammograms (Taylor et al, 1999) and chemotherapy dosage
decisions in paediatric ALL (Bury et al, 2005).
Most decision support techniques have tended to focus on
isolated decision nodes in the care process, for example, drug
dosing (Manotti et al, 2001) or ECG analysis (Selker et al, 1998),
rather than on a ‘patient journey’ as an integrated and coordinated
whole. Our work on the CREDO project (Fox et al, 2006) is
designed to support the entire journey of breast cancer patients,
from initial presentation and diagnosis through to treatment and
follow-up. As part of the CREDO project we have developed a
formal model of a care pathway for the management of women
with breast cancer, or at risk of developing breast cancer, as a
foundation for the design of the decision support and other
services based on published CPGs and other evidence-based
sources. The model shows that there may be as many as 65
separate decision points in the breast cancer journey where if best
evidence-based practice is not complied with there is significant
potential for patient harm, or at least failure to achieve the best
outcome.
There were two purposes of the present study. First, to
investigate whether decision support technology can significantly
enhance the compliance of breast clinicians with best practice as
defined by evidence-based guidelines. Second, to determine the
benefits of a specific approach to decision support in CREDO. The
focus of the study is the initial (triple) assessment of patients
referred to breast clinics with symptoms of possible cancer. In the
United Kingdom triple assessment (TA) clinics are carried out by
the members of a multidisciplinary team to diagnose and manage
symptomatic patients. Such clinics involve decision-making based
on clinical examination, radiological, and pathological investiga-
tions conducted in one session with the aim of speeding up
diagnosis and treatment. The Triple Assessment Decision Support
system (TADS) is designed to assist at four decision points (family
history and genetic risk assessment, selection of imaging and
biopsy modalities, and final management decision).
MATERIALS AND METHODS
PROforma tools for modelling clinical guidelines and
pathways
The TADS system was constructed using the PROforma guideline
and workflow modelling language (Fox and Das, 2000) and the
Tallis process modelling system developed by Cancer Research UK
(www.acl.icnet.uk/TallisTraining).
The key difference from the SOR approach is that the PROforma
model can be executed by a computer and displayed at the clinical
point of care using, for example, a web browser. Tallis provides
many ways of delivering decision support but a straightforward
implementation would provide electronic data forms for recording
patient data, automatic scheduling of clinical tasks and display of
SOR standards and, if required, making patient-specific recom-
mendations for diagnostic or therapeutic options according to
patient data and clinical circumstances. In this way a PROforma
service can deliver conventional guidelines such as SOR guidelines
while adding patient-specific decision support and many other
data and knowledge management services.
TA mode
TADS was designed to support a breast clinician taking a patient
through the TA clinic. Figure 1 shows the Tallis representation of
Figure 1 Tallis representation of TA workflow showing the main plan. The decision nodes represented by circles are embedded at various points in the
workflow.
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sTA workflow, which involves abstracting data from family history,
medical history, clinical examination of a patient and making
decisions about risks, and diagnostic interventions and manage-
ment.
1. Four key inter-dependent decision points were identified in the
TA workflow:
2. Genetic risk assessment: low, medium or high (taken as part of
the clinical history plan)
3. Radiological investigations to perform: mammogram, ultra-
sound, both or none
4. Biopsy method to perform: (FNA, core biopsy, and other
investigations)
5. Management decision: whether to refer the patient to a
multidisciplinary team and/or to geneticist, to discharge or to
follow-up (high-risk surveillance).
Designing the medical knowledge base
Evidence-based guidelines (see Table 1) were used to define the
logical reasoning about patient data as a set of arguments for and
against each option, for each of the four decisions. All selected
CPGs scored high (overall score of 460% in all domains) on a 23-
point AGREE scale (The AGREE collaboration, 2003) suggesting
their high rigour. An expert panel was formed comprising four
senior practising consultants from four relevant disciplines
(surgery, radiology, pathology, and genetics). The panel reviewed
the knowledge base for its accuracy in encoding the evidence-
based guidelines and consensus was achieved.
Hypothetical cases
We developed 15 hypothetical cases, designed to cover a range of
risk levels and clinical scenarios. Cases were adapted from a larger
number of real cases referred to the Guy’s Hospital TA clinic over
a period of 6 months. We specified all the patient data that would
be required for taking all four key decisions, such as complete
medical and family history, complete examination findings, and
test results. The set of 15 cases was reviewed by the expert panel for
the adequacy of data, as well as for internal consistency and
generalisability.
A knowledge base of 125 evidence-based arguments/facts
derived from the guidelines allowed TADS to mimic exactly the
expert panel’s recommendations for all decisions in the test set of
15 cases. From these 15 cases, three sets of five simulated cases
were established, each set taking a variety of scenarios.
Design of the study
We performed a crossover experiment with balanced block design
in which participating clinicians were asked to address the cases,
with and without decision support. A total of 36 breast clinicians
were opportunistically sampled from the population of breast
cancer clinicians who routinely conduct TA clinics in the south
east of the England. In all, 24 agreed to participate in the trial.
For the trial, TADS was designed to run in two ‘modes’ with
decision support either enabled or disabled. In both modes, the
patient information required to take a decision is displayed on the
computer screen at the decision point. In decision support enabled
mode (DSþ), recommended decision options are highlighted by
green ticks; non-recommended options are marked by red crosses.
The user can also see the medical reasons for and against each
option, along with hyperlinks to the referring guideline and
underlying literature evidence (see Figure 2). However, the user
always has the freedom to override system recommendations.
In decision support disabled (DS ) mode, the system displays
the list of options without highlighting recommendations (see
Figure 3). In both modes, the system anonymously captures and
keeps track of the options selected by the user at each decision
point, together with a record of what its own recommendation
would have been in the DSþ mode.
Each participating clinician was assigned to address two sets of
cases: one set with and one set without decision support.
Assignment as to whether decision support was to be made
available for the first or second set was randomly balanced to
control for any learning effect. To control for differences in the
difficulty of the case sets, the three sets of five cases were also
balanced so that each set was addressed the same number of times
in each arm of the trial. We refer to each patient being taken
through the four decisions by one subject as a ‘patient journey’, so
in total 120 patient journeys (24 clinicians going through a set of
five patients) were made with decision support and 120 without.
Sessions were conducted using a laptop computer in offices/
clinics in the various hospitals in which the participating clinicians
worked. All subjects were familiarised with the system using a
prepared training script. Throughout each session, subjects had
access to each patient’s data on paper as well as via TADS web
pages.
Statistical method
After the experiment was completed, the decisions made by each
clinician for each patient case were compared to guideline
recommendations as determined by our expert panel. Each ‘patient
journey’ was categorised as either ‘with deviations’, or ‘without
deviation’.
Deviations were empirically categorised by the expert panel as
follows:
  Minor or non-critical deviations that arguably would not result
in direct patient harm.
  Critical deviations that could potentially result in patient harm.
A further subgroup of critical deviations was identified as
irretrievable critical deviations, where a patient completed the
journey and was discharged. In practice, such errors would
typically not be spotted or rectified by other members of the team.
The analysis of the patient journeys was carried out on a per
clinician basis. The number of patient journeys that contained
errors or deviations in both decision support and no decision
support arms were compared using a Wilcoxon signed rank test.
We had 80% power to find a 15% significant difference (P¼0.05).
Table 1 Guidelines used in the DSS
Specialty Guidelines
AGREE
score
Genetic risk assessment NICE: Familial breast cancer
guideline
88
Diagnosis SIGN: Management of breast
cancer in women
82
BASO: Guidelines for surgeons in
the management of symptomatic
breast disease in the UK
69
NCCN: Breast Cancer Screening
and Diagnosis guidelines
75
Imaging ACR: Appropriateness Criteria 70
NHSBSP guidelines: Breast cancer
screening assessment (Pub. 49)
63
Pathology NHSBSP guidelines: Non-operative
diagnostic procedures and
reporting in breast cancer screening
(Pub. 50)
63
DSS¼Decision Support System. The table includes overall AGREE score for each
clinical practice guideline out of a maximum score of 92.
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Population characteristics
The majority of our study population were male consultant breast
surgeons with intermediate computing skills. On average, they
were 42.9 years old with 9.4 years experience in the speciality of
breast cancer and had been conducting 1.8 TA clinics a week for
6.5 years.
The average time taken by each clinician to complete 10 patient
journeys was 37.2min ranging from 24 to 61min.
Analysis of deviations
Sixty out of 120 patient journeys undertaken in the DS  condition
included at least one deviation (see Table 2), compared with only
16 out of 120 supporting the DSþ condition (Po0.001). Out of a
total of 60 deviations in the DS  arm of the trial, 16 were identified
as potentially critical, compared to only one in the DSþ arm
(P¼0.001). In all, 10 out of 120 patient journeys without decision
support involved at least one deviation that was irretrievable and
potentially critical, compared to only one out of 120 with decision
support (P¼0.02).
Examples of deviations or errors recorded in the study
Minor or non-critical deviations
  Requesting ultrasound as a screening tool in the absence of any
localised abnormality
  Not requesting ultrasound for breast mass
  Overestimating familial breast cancer risk
  Underestimating familial breast cancer risk
  Unnecessary referral to a geneticist (of a low-risk patient)
  Unnecessary referral to multidisciplinary team.
Figure 2 TADS screen with decision support enabled, showing decision options for the imaging for one case, to be taken after medical history and
examination. The system recommends an ultrasound scan but recommends against mammography and against doing nothing. For the decision option ‘Do a
mammogram of both breasts’, arguments for and against have been expanded to show the justifying evidence (an option available to the clinician for all
decisions, options and arguments). Links are provided to the relevant supporting literature, which can be accessed by the user if required (e.g. from PubMed).
Figure 3 TADS screen with decision support disabled, showing options for imaging after medical history and examination have been presented.
Evidence-based guidelines and decision support services
V Patkar et al
1493
British Journal of Cancer (2006) 95(11), 1490–1496 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sPotentially critical deviations
  Failing to perform FNA/biopsy in the event of a localised clinical
abnormality and normal imaging.
  Not requesting ultrasound when a mammogram showed
localised density/mass.
  Failing to carry out a repeat biopsy when the FNA report for a
breast lump was inconclusive.
  Failing to request a mammogram for symptomatic women over
35 years with high genetic risk.
  Failing to request a mammogram for a pregnant woman when
clinical examination and ultrasound were both highly suggestive
of malignancy.
  Not requesting a mammogram for a symptomatic woman over
30 years with high risk owing to mantle radiotherapy in childhood.
Questionnaires
At the end of the trial, we conducted a questionnaire study with
participants to learn more about their thoughts on the system. An
opinion on a five-point Likert scale, to the most basic statement:
‘patient care in TA would benefit from computerised decision
support’, was obtained from participants both before and after use
of the system. To investigate the change in opinion we used the
Fleiss Everitt simplification of the Stuart Maxwell test for matched
pairs (Fleiss, 1981) to look for a change in distribution of opinion
and then checked for systematic differences using the McNemar
test (McNemar, 1947). Overall, 10 clinicians maintained the same
opinion of TADS both before and after the experiment; 11 became
more convinced of its benefit and two became one category less
convinced (Table 3).
There was a highly significant difference in the change in
distribution of opinion (matched pair, 3d.f., w
2¼10.26, and
Po0.01). One person who disagreed with the statement before
did not change his mind afterwards, but of the 16 who were
undecided before, 10 changed their minds to agree with the
statement (2d.f., w
2¼8.1, and Po0.025).
SUMMARY AND DISCUSSION
The results obtained in this study suggest that a decision support
tool like TADS that supports multiple decisions in a care pathway
can significantly reduce deviations from best practice. Though the
majority of deviations observed were empirically characterised as
minor, those that involved unjustified referrals and unnecessary
tests could have had an adverse impact on resource usage and also
costs. After excluding minor deviations, differences remained
significant even for the small number of irretrievable deviations
that were potentially critical. There was an overall significant
positive shift in the opinions of participating clinicians towards
TADS after they had used it.
This study forms part of the CREDO project, which is
investigating whether evidence-based decision support technology
can help to improve quality and safety of decision making in
cancer care, and in particular whether PROforma technology can
provide comprehensive support for the real cancer journey, taking
breast cancer as a model. Previous studies have looked at use of
CDSS systems in genetic risk assessment (for breast and ovarian
cancer) and detection and interpretation of abnormalities in
mammograms, with promising results. This study represents a
significant advance on these studies by considering TA, which is
an important and more complex component of breast cancer
management. Where earlier studies focused on a single decision,
TADS includes four interdependent decisions as well as manage-
ment of the clinical workflow required to provide a TA service.
The study adds to a growing body of evidence that decision
support systems have significant value, both because of the focus
in cancer, where there is still relatively little specific evidence about
use of CDSSs and because almost all CDSS results, which have been
systematically reviewed, have only considered individual decisions.
The results give increased confidence that the CREDO objective of
supporting the whole cancer journey is technically practical, that it
could provide measurable benefits, and that such services will be
acceptable to cancer professionals.
The results of the study may, however, need to be treated with
some caution.
First, the study was conducted with simulated patients; the
simulations were based on real cases but for this systematic
comparison of decision making with and without decision support
ethical and practical constraints forced us to use computer-based
presentation of patient data rather than real patients. In previous
research, however, simulated case scenarios have been shown to be
good predictors of clinical performance (O’Hagan et al, 1986). Our
Table 2 Analysis of deviations in decision support and no-decision support arms
Without decision support (Total 120
patient journeys)
With decision support (Total 120 patient
journeys)
Type of
deviation
Patient journey
with at least one
deviation of
given type
Patient journey
without any
deviation of
given type
Patient journey
with at least one
deviation of
given type
Patient journey
without any
deviation of
given type
P value by
Fisher’s exact
All deviations 60 60 16 104 o0.001
Potentially critical
deviations
16 104 1 119 o0.001
Potentially critical
irretrievable
deviations
10 110 1 119 0.01
Table 3 Responses to the statement: ‘patient care in triple assessment
would benefit from computerised decision support’
Before using TADS After using TADS system
Strongly agree 3 3
Agree 3 13
Undecided 16 6
Disagree 1 2
Strongly disagree 1 0
Total 24 24
TADS¼The Triple Assessment Decision Support System. Ten clinicians maintained
the same opinion of TADS before and after; 11 became more convinced of its
benefit; two became one category less convinced of its benefit.
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pages, but paperless records have been shown to be more
understandable than paper-based records (Hippisley-Cox et al,
2003) and subjects in the control group were forced to consider all
pertinent patient data and make all decisions in our simulation.
Continued exposure to CDSSs may improve clinical performance
still further as users get more experienced in their use. In other
studies we have asked actors to play the role of patients, with similar
results in terms of improved decision-making. Using trained actors
to role-play patients is an accepted technique which accurately
predicts behaviour in real clinical settings but is still a very
demanding evaluation technique in complex, multi-decision settings
like TA. Given the generally positive results reported in studies of
CDSSs and in the absence of a reason to suggest that our results
could be an artefact of the simulation we are inclined to accept the
findings. For the present, however, the results must be treated as
indicative rather than definitive until a full RCT has been completed.
Second, the simulated cases were deliberately more varied than
one would find in a typical TA clinic. One of our aims was to test
the effect of the software in differing scenarios. Consequently,
more diverse cases than one would typically find in 15 cases
chosen at random were presented. It may also be argued that our
study sample of doctors was not representative but consisted of a
self-selecting group of sufficiently computer literate clinicians.
However, we see no reason to doubt the apparently substantial
benefits of decision support purely on this variety; rather the
reverse. Indeed only six clinicians thought that their decision-
making in TA would benefit from decision support before they
participated in the study while after participation this figure
increased to 16.
The SOR methodology is a particularly relevant context in which
to consider the extension of CPGs to include decision support
capabilities because it has been developed primarily with cancer
applications in mind, and because the participants in the SOR
programme have created a great deal of oncological content which
might be enhanced with decision support functions. The
PROforma approach seems well suited to adding value to SOR
CPGs because of the straightforward mapping between SORs and
the PROforma decision model. This model is based on the
automated construction of arguments for and against decision
options, where each argument has an explicit logical justification
together with an evidence-based grounding in published research.
PROforma can also be used to add value to other document-centric
guideline systems like GEM (Shiffman et al, 2004) but the SOR
method is attractive because of the rigorous approach taken to the
creation of a large set of cancer CPGs. We may also note that
PROforma can offer a variety of additional services over and above
decision making which are relevant to routine cancer care,
including treatment planning and the management of clinical
trials and capture of patient data with electronic CRFs.
ACKNOWLEDGEMENTS
We thank the 24 clinicians who spared their time to help us. We
also thank the expert panel, from Addenbrooke’s and Guy’s, who
reviewed our guideline content and determined the appropriate
decision options for our simulated cases: Professor Ian Fentiman
(Surgeon), Dr Ruth Warren (Radiologist), Dr D’Arrigo Corrado
(Pathologist), and Dr Louise Izatt. (Geneticist)
Thanks to Dr Alyssa Alabassi, Dr Victoria Monaghan, and Mike
Bradburn for their input into the inception of this project. Also,
thanks to Dr Tony Rose for his part in working on the genetic risk
assessment component of the guideline model.
Contributors: VP and CH have contributed equally in this study.
VP, CH, MW, and SL developed the study protocol. VP, MW, and
CH conducted the intervention. SL performed the analysis. JF and
AP conceived and supported the research. JF and RT contributed
to the drafting of the paper. The software was implemented by VP,
CH, and RS. VP acts as a guarantor for the study.
Funding: Cancer Research – UK funded the study.
REFERENCES
Aylin P, Tanna S, Bottle A, Jarman B (2004) How often adverse events are
reported in English hospital statistics? BMJ 329: 369
Bloom BS, de Pouvourville N, Chatre S, Jayadevappa R, Weinberg D (2004)
Breast cancer treatment in clinical practice compared to best evidence
and practice guidelines. Br J Cancer 90(1): 26–30
Bury J, Hurt C, Roy A, Cheesman L, Bradburn M, Cross S, Fox J, Saha V
(2005) LISA: a web-based decision-support system for trial management
of childhood acute lymphoblastic leukaemia. Br J Haematol 129(6):
746–754
Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin
HR (1999) Why don’t physicians follow clinical practice guidelines? A
framework for improvement. JAMA 282: 1458–1465
Commission for Health Improvement/Audit Commission (2001) National
Service Framework Assessments No.1. NHS Cancer Care in England and
Wales. London, UK: Commission for Health Improvement, (accessed
November 01 2006 http://www.healthcommission.org/_db/_documents/
04000018.pdf)
Corrigan JM, Donaldson MS, Kohn LT, Maguire SK, Pike KC (2001) A New
Health System for the 21st Century. Washington, DC: Institute of
Medicine, National Academy of Sciences, National Academies Press;
Crossing the Quality Chasm
Emery J, Walton R, Murphy M, Austoker J, Yudkin P, Chapman C, Coulson
A, Glasspool D, Fox J (2000) Computer support for interpreting family
histories of breast and ovarian cancer in primary care: comparative study
with simulated cases. BMJ 321(7252): 28–32
Fervers B, Hardy J, Blanc-Vincent MP, Theobald S, Bataillard A, Farsi F,
Gory G, Debuiche S, Guillo S, Renaud-Salis JL, Pinkerton R, Bey P, Philip
T (2001) SOR: project methodology. Br J Cancer 84(Suppl 2): 8–16
Field MJ, Lohr KN (eds) (1990) Institute of Medicine Committee to Advise
the Public Health Service on Clinical Practice Guidelines. Clinical practice
guidelines: directions for a new program. Washington DC: National
Academy Press
Fleiss JL (1981) Statistical methods for rates and proportions 2nd edn, New
York: Wiley
Fox J, Das S (2000) Safe and Sound: Artificial Intelligence in Hazardous
Applications. MIT Press: Cambridge
Fox J, Patkar V, Thomas R (2006) Decision support for healthcare: the
PROforma evidence base. Inform Prim Care 14(1): 49–54
Freemantle N, Harvey EL, Wolf F, Grimshaw JM, Grilli R, Bero LA (1996)
The effectiveness of printed educational materials in changing the
behaviour of health care professionals Cochrane Collaboration. Cochrane
Library. Issue 3. Oxford: Update Software
Garg AX, Adhikari NK, McDonald H, Rosas-Arellano MP, Devereaux PJ,
Beyene J, Sam J, Haynes RB (2005) Effects of computerized clinical
decision support systems on practitioner performance and patient
outcomes: a systematic review. JAMA 293(10): 1223–1238
Grimshaw J, Eccles M, Walker A, Thomas R (2002) Changing physician’s
behaviour: what works and thoughts on getting more things to work.
J Cont Educ Health Prof 22: 237–243
Grol R, Grimshaw J (2003) From best evidence to best practice: effective
implementation of change. Lancet 362: 1225–1230
Hippisley-Cox J, Pringle M, Cater R, Wynn A, Hammersley V, Coupland C,
Hapgood R, Horsfield P, Teasdale S, Johnson C (2003) The electronic
patient record in primary care – regression or progression? A cross-
sectional study. BMJ 326: 1439–1443
James BC, Hammond MEH (2000) The challenge of variation in medical
practice. Arch Pathol Lab Med 125: 1001–1003
Kohn LT, Corrigan JM, Donaldson MS (eds) (1999) To Err Is Human:
Building a Safer Health System, Committee on Quality of Health Care in
America. Washington, DC: Institute of medicine, National Academy Press
Evidence-based guidelines and decision support services
V Patkar et al
1495
British Journal of Cancer (2006) 95(11), 1490–1496 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sManotti C, Moia M, Palareti G, Pengo V, Ria L, Dettori AG (2001) Effect of
computer-aided management on the quality of treatment in antic-
oagulated patients: a prospective, randomized, multicenter trial of
APROAT (Automated PRogram for Oral Anticoagulant Treatment).
Haematologica 86: 1060–1070
McNemar Q (1947) Note on the sampling error of the difference between
correlated proportions or percentages. Psychometrika 12: 153–157
O’Hagan JJ, Davies LJ, Pears RK (1986) The use of simulated patients in the
assessment of actual clinical performance in general practice. NZ Med J
99: 948–951
Selker HP, Beshansky JR, Griffith JL, Aufderheide TP, Ballin DS, Bernard
SA, Crespo SG, Feldman JA, Fish SS, Gibler WB, Kiez DA, McNutt RA,
Moulton AW, Ornato JP, Podrid PJ, Pope JH, Salem DN, Sayre MR,
Woolard RH (1998) Use of the acute cardiac ischemia time-insensitive
predictive instrument (ACI-TIPI) to assist with triage of patients with
chest pain or other symptoms suggestive of acute cardiac ischemia: a
multicenter, controlled clinical trial. Ann Intern Med 129: 845–855
Shiffman RN, Michel G, Essaihi A, Thornquist E (2004) Bridging the
guideline implementation gap: a systematic, document-centered approach
to guideline implementation. J Am Med Inform Assoc 11(5): 418–426
Taylor P, Fox J, Pokropek AT (1999) The development and evaluation of
CADMIUM: a prototype system to assist in the interpretation of
mammograms. Med Image Anal 3(4): 321–337
The AGREE collaboration (2003) Development and validation of an
international appraisal instrument for assessing the quality of clinical
practice guidelines: the AGREE project. Qual Saf Health Care 12: 18–23
Evidence-based guidelines and decision support services
V Patkar et al
1496
British Journal of Cancer (2006) 95(11), 1490–1496 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s